Vida Ventures — Full Portfolio

Praxis Precision Medicines is a central nervous system precision neuroscience biopharmaceutical company developing therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance, with a pipeline spanning movement disorders and epilepsy.

BiotechDeep TechHealthtechBoston, US

SPSteve Petrou(Co-Founder, President of Research & Development)inKRKiran Reddy(Executive Officer, Director)inMarcio Souza(President & Chief Executive Officer)in

BoardNicholas G. Galakatos(Director)in

Board seatStefan Vitorovic· per SEC Form D

Co-investorsAVAvoro Capital AdvisorsCACapria VenturesOCOCV PartnersALAlameda ResearchAPAPOLLO PROJECTSBLBlackstone+6 more

Allogene Therapeutics develops allogeneic CAR T cell therapies (AlloCAR T) for blood cancers, solid tumors, and autoimmune diseases, using off-the-shelf manufactured cell products rather than patient-derived autologous approaches.

BiotechHealthtechMedical DevicesSouth San Francisco, US

ABArie Belldegrun, M.D.(Executive Chairman and Co-Founder)inDCDavid Chang, M.D., Ph.D.(Co-Founder, Allogene; former President and Chief Executive Officer)CCChristine Cassiano(Executive Vice President, Chief Corporate Affairs and Brand Strategy Officer; one of the founders of Allogene)inZachary Roberts, M.D., Ph.D.(President and Chief Executive Officer)ROBERT ABRAHAM(Director)JAJOSHUA A. KAZAM(Co-Founder and Director of Allogene)

Co-investorsAVAvoro Capital AdvisorsFOForesite CapitalTPTPGGIGilead Sciences

Avalyn Pharma develops inhaled therapies for pulmonary fibrosis, using a nebulization approach that delivers treatment directly to the lungs to reduce the tolerability problems of existing oral therapies.

BiotechHealthtech

LBLyn Baranowski(CEO)in

Co-investorsANAndera PartnersCACatalio Capital Management, LPF-F-Prime CapitalINInVivium CapitalNONorwest Venture PartnersPIPivotal Life Sciences+9 more

Dyne Therapeutics develops targeted therapies for genetically driven neuromuscular diseases using its proprietary FORCE platform.

BiotechMedical DevicesWaltham, US

Romesh Subramanian, Ph.D.(Executive Officer)Richard Scalzo(Executive Officer)Joshua Brumm(Executive Officer, Director)Jonathan McNeill, M.D.(Executive Officer)inOBOxana Beskrovnaya, Ph.D.(Executive Officer)JGJohn G. Cox(President and Chief Executive Officer)in

Co-investorsATAtlas VentureHEHercules Capital, Inc.MPMPM BioImpactWEWellington ManagementFOForbionRARA Capital

Kyverna is a clinical-stage biopharmaceutical company developing CAR T-cell therapies to treat autoimmune diseases through B cell depletion and immune system reset.

BiotechEmeryville, US

WBWarner Biddle(Chief Executive Officer)inBrian Kotzin(Director)Ian Clark(Director)Ryan Jones(Executive Officer)Karen Walker(Executive Officer)PMPeter Maag(Executive Officer, Director)in

Co-investorsBABain Capital Life SciencesWEWestlake Village BioPartnersGIGilead SciencesINInsight PartnersKLKleiner PerkinsNONorthpond Ventures+3 more

A clinical-stage biopharmaceutical company developing small molecule therapies for schizophrenia, bipolar depression, and other neuropsychiatric disorders.

BiotechHealthtechNew York, US

ZPZachary Prensky(Executive Officer, Director)inLauren Stipp(Executive Officer)Mark Panoff(Executive Officer)Heather Turner(President & Chief Executive Officer and Director)Gad Soffer(Chief Operating and Business Officer)Anna Eramo(Chief Medical Officer)

Co-investorsPIPivotal Life SciencesPOPontifax Venture CapitalTATarnagulla VenturesTCTCG Crossover

Sutro is a biotech company developing a cell-free protein synthesis platform for the design and manufacturing of complex biologics, particularly cancer therapies and antibody-drug conjugates.

BiotechDeep TechHealthtechMedical DevicesSouth San Francisco, US

William J. Newell(Executive Officer, Director)JCJane Chung(Chief Executive Officer)inHGHans-Peter Gerber(Chief Scientific Officer)inDPDavid Pauling(Chief Administrative Officer and General Counsel)inJFJonathan Fawcett(VP, Head of Clinical Development)inDevendra Luhar(SVP, Technical Operations)in

Co-investorsOWOwl CapitalRIRidgeback CapitalSASamsara BioCapitalSOSolasta VenturesSVSV Health Investors

Adcendo develops antibody-drug conjugates (ADCs) engineered to treat cancers with high unmet medical needs.

BiotechDigital HealthMedical Devices

Co-investorsYSYsios CapitalHEHealthCapJEJeito Capital

Adcendo develops antibody-drug conjugates (ADCs) targeting cancers with high unmet medical need.

BiotechMedical DevicesCopenhagen, DK

Michael Pehl, MSc(Chief Executive Officer)

Co-investorsHEHealthCapJEJeito CapitalNONovo HoldingsOROrbiMedPOPontifax Venture CapitalRARA Capital+3 more

Antares Therapeutics discovers and develops precision medicines, with a focus on small molecule therapies targeting previously undruggable oncology targets and other serious diseases.

AI & Machine LearningBiotechMedical DevicesCambridge, US

AFAdam Friedman(Chief Executive Officer)inAFAndrew Fedder(Executive Officer, Director)inBPBrian Piper(Executive Officer, Director)in

Co-investorsATAtlas VentureLILightspeed Venture PartnersOMOmega FundsTETenmileABAbingworthALAlleyCorp+1 more

InduPro develops next-generation protein therapeutics by leveraging inherent and induced proximity to modulate disease biology, with a focus on ADCs and T-cell engagers.

BiotechDeep TechMedical DevicesSeattle, US

KCK. Chris Garcia(Scientific Founder)PRPrakash Raman(CEO)inAJAmanda J. Redig(Chief Medical Officer)inSLScott Lesley(President & CSO)inPHPamela Holland(SVP of Biology)inSJSally Johnson(Chief People Officer)in

Co-investorsMRMRL Ventures FundTHThe Column Group

SonoThera is developing a nonviral, non-invasive gene delivery technology that uses ultrasound and microbubbles (ultrasound-mediated delivery) to deliver genetic payloads to targeted sites in a redosable way.

BiotechDeep TechDigital HealthHealthtechSouth San Francisco, US

KGKenneth Greenberg(Co-Founder, President & CEO)in

Co-investorsLELeaps by BayerARARCH Venture PartnersFOFoothill VenturesILIllumina VenturesMEMedical Excellence CapitalVIVivo Capital+8 more

A2 Bio develops precision CAR T-cell therapies using its Tmod cell engineering platform, supporting both autologous and allogeneic applications.

BiotechDeep TechDigital HealthHealthtechMedical DevicesAgoura Hills, US

CAC. Alexander Kamb(Director)inJRJim Robinson(CEO)inScott Foraker(Executive Officer, Director)Madhavan Balachandran(Director)Michael Gallo(Director)

BoardSASrini Akkaraju(Director)in

Board seatHSHelen S. Kim· per SEC Form D

Co-investorsCACasdin CapitalMAMana VenturesNENextech InvestTHThe Column GroupSASamsara BioCapital

ByHeart is an infant formula company that manufactures science-driven baby formula with its own manufacturing process and supply chain.

ConsumerDirect to ConsumerFoodTechHealthtechNew York, US

RBRon Belldegrun(Co-founder)inMFMia Funt(Founder)inGKGeorg Krause-Vilmar(Executive Officer)inNMNiall Mullane(Executive Officer)in

BoardASAmy Schulman(Director)HZHemi Zucker(Director)in

Board seatABArie BelldegrunJKJoshua Kazam· per SEC Form D

Co-investorsEVEvolution VC PartnersGAGaingelsOCOCV PartnersRERed Sea VenturesAFAF VenturesPOPolaris Partners

Iconovir is a biotechnology company focused on developing cancer treatments, with a stated mission to cure cancer and restore life to patients.

BiotechHealthtechNew York, US

SASean Algeo(Executive Officer, Promoter)inMAMark A. McCamish(Executive Officer, Director)inDMDavid M. Tanen(Executive Officer, Promoter)

BoardDCDavid Chang(Director, Promoter)HKHelen Kim(Director)JLJakob Loven(Director)in

Board seatHSHelen S. KimJKJoshua KazamABArie Belldegrun· per SEC Form D

Co-investorsGVGV (Google Ventures)NENextech InvestWEWellington Management

Kronos Bio was a clinical-stage biopharmaceutical company developing small molecule therapeutics that target deregulated transcription factor networks implicated in cancer.

BiotechNew York, US

Norbert Bischofberger, Ph.D.(Executive Officer, Director)Christopher Wilfong(Executive Officer)

BoardRebecka Belldegrun, M.D.(Director)Otello Stampacchia, Ph.D.(Director)DMDavid M. Tanen(Executive Officer, Director, Promoter)Arie S. Belldegrun, M.D.(Director)

Board seatJKJoshua Kazam· per SEC Form D

Co-investorsECEcoR1 CapitalGVGV (Google Ventures)NENextech InvestBLBlackRockCOCommodore CapitalINInvus+2 more

Clinical-stage biotech developing neoantigen-targeted T cell receptor (TCR) therapies for cancer; acquired by AstraZeneca.

BiotechNew York, US

Carsten Linnemann, PhD(Executive Officer, Director, Promoter)Antonius N.M. Schumacher(Director)Fei Chen(Director)

BoardDMDavid M. Tanen(Director, Promoter)HKHelen Kim(Director)

Board seatRJRajul Jain· per SEC Form D

Co-investorsECEcoR1 CapitalJEJeito CapitalTPTPG

ReCode develops mRNA and gene correction therapeutics for genetic diseases, using proprietary lipid nanoparticle technology to deliver treatments to specific organs.

AI & Machine LearningBiotechHealthtechMedical DevicesMenlo Park, US

Dr. Daniel J. SiegwartArthur E Johnson(Executive Officer, Director)

Board seatHSHelen S. Kim· per SEC Form D

Co-investorsAJAju IB InvestmentECEcoR1 CapitalEVEvolution VC PartnersMPMPM BioImpactOROrbiMedOUOUP (Osage University Partners)+6 more

Tectonic is a clinical-stage biotechnology company developing therapeutic proteins and antibodies that target G-Protein Coupled Receptors (GPCRs) using a proprietary platform called GEODe™.

AI & Machine LearningBiotechMedical DevicesWatertown, US

TATimothy A. Springer(Co-Founder)Andrew C. Kruse(Director)Alise Reicin(Executive Officer, Director)inDaniel Lochner(Executive Officer)MSMarc Schwabish(Executive Officer)inPMPeter McNamara(Executive Officer)in

Board seatStefan Vitorovic· per SEC Form D

Co-investorsECEcoR1 CapitalALAlly Bridge GroupCLClarus VenturesFAFarallon EquitiesPOPolaris PartnersSOSoleus Capital

An R&D-driven biopharmaceutical company that uses AI to develop breakthrough medicines and vaccines focused on immune system disorders across five therapeutic areas.

AI & Machine LearningBiotechMedical DevicesCambridge, US

IMIvana Magovcevic-Liebisch(Executive Officer, Director)CVChristopher Verni(Executive Officer)inMary Thistle(Director)Evan Thackaberry(Executive Officer)Suzanne Bruhn(Director)Gerhard Koenig(Director)

Board seatStefan Vitorovic· per SEC Form D

Co-investorsATAtlas VentureHAHatteras Venture PartnersLILightstone VenturesPIPivotal Life SciencesLOLongwood Fund

Volastra Therapeutics is a drug discovery and development company working on novel cancer therapies.

BiotechHealthtechNew York, US

SBSamuel Bakhoum(Co-Founder & Chief Scientific Officer)inLewis Cantley(Founder and Chair of Scientific Advisory Committee)Olivier Elemento(Founder and Scientific Advisor)DPDavid P. Southwell(Chief Executive Officer)in

BoardRMRobert Mittendorff(Director)inJGJill Goldstein(Director)in

Board seatStefan Vitorovic· per SEC Form D

Co-investorsDRDroia VenturesARARCH Venture PartnersB B Capital GroupB4B4 CapitalCACatalio Capital ManagementPOPolaris Partners

Affini-T Therapeutics develops TCR-based immunotherapies aimed at treating solid tumors, using two complementary therapeutic modalities.

BiotechHealthtechLongevity

Co-investorsAGAgent CapitalJAJacket River Capital PartnersOLOlive Tree CapitalSEService Provider CapitalFRFred Hutchinson Cancer Research CenterHUHumboldt+1 more

BiotechWatertown, US

Kathy Bergsteinsson(Executive Officer)inKYKathy Yi(Executive Officer)inJoseph Knowles(Executive Officer, Director)

BoardLILucio Iannone(Director)inArjun Goyal(Director)Jill DeSimone(Director)

Co-investorsLELeaps by Bayer

Alterome is a clinical-stage precision oncology company developing small-molecule, alteration-specific cancer therapies, with two internally discovered drug candidates in the clinic.

AI & Machine LearningBiotechDeep TechSan Diego, US

EAEric A. Murphy(Executive Officer, Director, Promoter)inRyan B. Corcoran(Director, Promoter)Richard Heyman(Founder)

BoardTSThilo Schroeder(Director)inCGCarl Gordon(Director)inAGArjun Goyal(Director)in

Co-investorsCACanaan PartnersNENextech InvestOROrbiMedDIDigitalis VenturesNVNVIDIA

AskBio is a gene therapy company developing adeno-associated virus (AAV)-based genetic medicines for rare and other diseases, with clinical programs such as AB-1009 for late-onset Pompe disease.

BiotechDeep TechHealthtechDurham, US

SMSheila Mikhail(CEO, Treasurer and Secretary)inRichard Samulski(President and Chief Science Officer)Katherine Wood(Director)Fred Cohen(Director)Javier Garcia(Director)John Schilling(Director)

Co-investorsCOColumbus Venture PartnersTPTPG

Attovia is a biotechnology company focused on drug development and clinical strategy, aiming to bring treatments to patients where none exist and create next-generation therapeutic options.

BiotechDigital Health

ZOZaneta Odrowaz(Founder)inTFTao Fu, MBA, M.S.(Founder, Chief Executive Officer, and President)ZOZaneta Odrowaz, Ph.D.(Chief Business Officer and Co-Founder)Petter Veiby(Chief Scientific Officer and Co-Founder)inHangjun Zhan, Ph.D.(Chief Technology Officer and Co-Founder)

Co-investorsECEcoR1 CapitalFRFrazier Life SciencesILIllumina VenturesNENextech InvestSASanofi VenturesVEvenBio Partners+1 more

CandidRx develops T-cell engager antibodies to treat autoimmune diseases by redirecting T-cells to eliminate autoreactive B-cells.

BiotechHealthtechSan Diego, US

KSKen Song(Chairman, President and CEO)inKSKenneth Song, M.D.(Executive Officer, Director)AKArvind Kush(Executive Officer)TLTimothy Lu, M.D.(Executive Officer)inBernie Huyghe, Ph.D.(Executive Officer)

BoardJeffrey Tong, Ph.D.(Director)

Co-investorsFOForesite CapitalLILifeSci Venture PartnersOROrbiMedSASamsara BioCapitalTCTCG CrossoverTHThird Rock Ventures+2 more

AbbVie is a biopharmaceutical company that discovers and delivers medicines for immune-mediated diseases and other therapeutic areas globally.

BiotechHealthtechMedical DevicesSan Diego, US

ABAdrian Bot(Executive Officer)LSLaura Shawver(Executive Officer, Director)inRFRamin Farzaneh-Far(Executive Officer)inJustin Thacker(Executive Officer)Karen Smith(Director)Fabio Pucci(Director)

Co-investorsFIFinchley Healthcare VenturesPFPfizer Venture InvestmentsRARA CapitalSOSofinnova VenturesALAlexandriaFOForbion

CapWay was a fintech company focused on creating inclusive financial access, but the company has ceased operations.

FintechSaaSAtlanta, US

SASheena Allen(Founder)in

Co-investorsGAGaingelsNENew Orleans Startup FundSTStacked CapitalY Y CombinatorBABackstage CapitalCECedar Point Capital+14 more

Centessa is a biopharmaceutical company developing an Orexin Receptor 2 Agonist program aimed at treating sleep-wake, neurological, neurodegenerative, and neuropsychiatric disorders.

BiotechHealthtech

Co-investorsADAdvent Life SciencesECEcoR1 CapitalFOForesite CapitalGEGeneral AtlanticLILifeSci Venture PartnersMEMedicxi+4 more

BiotechMedical DevicesNew Haven, US

Scott Phillips(Executive Officer)in

BoardTSTim Shannon(Manager)inLRLiam Ratcliffe(Manager)in

Co-investorsACAccess BiotechnologyCACanaan PartnersCOConnecticut InnovationsELElm Street VenturesFRFrazier Life SciencesRARA Capital+1 more

Clinical-stage genetic medicines company using human-derived AAV vectors and nuclease-free gene editing for rare diseases.

BiotechBedford, US

Siyamak Rasty(Executive Officer)Albert Seymour(Executive Officer)

BoardSteven Gillis(Director)ATArthur Tzianabos(Executive Officer, Director)KPKush Parmar(Director)inRichard Gregory(Director)

Co-investors5A5AM VenturesARARCH Venture PartnersOUOUP (Osage University Partners)ALAlexandriaDEDeerfield Management CompanyFIFidelity Investments+5 more

Kite develops CAR T-cell therapies that engineer a patient's own immune cells to target and destroy cancer cells.

BiotechHealthtechSanta Monica, US

ASArie S. Belldegrun(Executive Officer, Director)inMargo R. Roberts(Executive Officer)CBCynthia Butitta(Executive Officer)inMBMarc Better(Executive Officer)inRizwana Sproule(Executive Officer)inArie Belldegrun(Founder)

Co-investorsALAlta PartnersPOPontifax Venture Capital

A healthcare company that develops and supplies medicines, including new and more affordable therapies, aiming for reliable supply of needed treatments.

BiotechHealthtechSan Francisco, US

JNJeffrey Nau(Executive Officer, Director)inMark A. Murray(Executive Officer, Director)D. Michael Ackermann(Director)

BoardWilliam J Link(Director)ABAli Behbahani(Director)in

Co-investorsFLFlying L PartnersNENew Enterprise Associates (NEA)VEVersant Venture AIV HoldingsVEVersant Ventures

Peloton Therapeutics is a clinical-stage pharmaceutical company developing first-in-class small molecule medicines targeting HIF-2α for cancer and other life-threatening conditions, with initial focus on kidney cancer and VHL disease.

BiotechDigital HealthMedical Devices

Co-investorsCUCurative VenturesFOForesite CapitalNENextech InvestRIRidgeback CapitalTHThe Column Group

Poplar Therapeutics is a company whose website provides informational content; based on its name it operates in therapeutics/biotech, though the available page (a privacy policy) does not describe its specific products or focus.

Biotech

Co-investorsRARA CapitalSRSR One Capital Management

Precision Medicine Group provides biomarker-driven research and development services and commercialization support for pharmaceutical and life science companies across drug development, manufacturing, and market access.

BiotechHealthtechMedical Devices

Co-investorsOAOak HC/FTOAOak Investment Partners

Protego Bio is a biotech company developing first-in-class therapies for protein misfolding diseases, including its lead candidate PROT-001 for AL amyloidosis, based on research into pharmacological chaperones.

AI & Machine LearningBiotechDeep TechDigital HealthHealthtechSan Diego, US

BJBrent J. Warner(Executive Officer, Director)inXIN JIANG(President & CEO)inHANK MICHAEL PETRASSI(Executive Officer)JEFFERY KELLY(Director)

BoardTIM LOHOFF(Director)Edward Hurwitz(Director)

Co-investorsDRDroia VenturesNONovartis Venture FundDIDigitalis VenturesFOForbionLILightspeed Venture PartnersMPMPM BioImpact+1 more

Quanta is a biotech company developing orally bioavailable, CNS-penetrant small-molecule KRAS inhibitors targeting RAS-driven cancers such as pancreatic, colorectal, lung, and endometrial cancers.

BiotechDeep TechHealthtechSouth San Francisco, US

Cameron Pitt(Executive Officer, Director)inDerek Metzger(Executive Officer)

BoardMKMaha Katabi(Director)inPNPerry Nisen(Executive Officer, Director)inMFMaria Fardis(Director)inRJRajul Jain(Director)in

Co-investorsFIFinchley Healthcare VenturesLOLongitude CapitalSOSofinnova VenturesBIBiotechnology Value FundFRFrazier Life Sciences

BiotechBoston, US

AFAdam Friedman(Executive Officer, Director)inGGGary Glick(Executive Officer, Director)inAndrew Fedder(Executive Officer)inDSDarrin Stuart(Executive Officer)inErica Jackson(Executive Officer)inAmanda Valentino(Executive Officer)

Co-investorsATAtlas VentureAVAvoro Capital AdvisorsECEcoR1 CapitalFRFrazier Life SciencesNENextech InvestABAbingworth+3 more

Soufflé Therapeutics develops nucleic acid medicines that precisely target and deliver genetic therapeutics to specific cell types to treat disease.

AI & Machine LearningBiotechDeep TechWatertown, US

VKVictor Kotelianski(Founder)DADaniel Anderson(Founder and Director)RLRobert Langer(Founder)MZMarino Zerial(Founder)BPBrad Pentelute(Founder)ANAmir Nashat, ScD(Founder, Director and CEO)

Co-investorsLELeaps by BayerBEBessemer Venture PartnersSASafar PartnersTCTCG CrossoverPOPolaris Partners

Third Arc Bio develops breakthrough treatments in oncology and immunology through advanced biologics engineering.

BiotechMedical DevicesLower Gwynedd, US

Joseph Erhardt(Executive Officer)inPeter Lebowitz(Executive Officer, Director)

BoardAGArjun Goyal(Director)inOtello Stampacchia(Director)inFDFrancesco Draetta(Director)in

Co-investorsANAndreessen HorowitzBIBiotechnology Value FundFOForesite CapitalHIHillhouse InvestmentOMOmega FundsT.T. Rowe Price